What is ImaginAb?
Established in 2007 and headquartered in California, ImaginAb operates at the intersection of biotechnology and diagnostic imaging. The company specializes in the development of novel imaging agents that provide physicians with real-time, actionable data regarding the efficacy of immuno-oncology treatments. By focusing on precision medicine, ImaginAb addresses a significant unmet need in the healthcare market: the ability to monitor drug response accurately and non-invasively. Their platform is designed to optimize patient selection, thereby reducing the trial-and-error approach often associated with advanced cancer therapies. As a key player in the diagnostic landscape, ImaginAb leverages its deep scientific expertise to support pharmaceutical partners and clinical researchers in improving patient outcomes through superior diagnostic clarity.
How much funding has ImaginAb raised?
ImaginAb has raised a total of $59.5M across 6 funding rounds:
Series A
$12.5M
Series B
$21M
Private Equity
$5.3M
Private Equity
$7.7M
Debt
$150K
Other Financing Round
$12.8M
Series A (2012): $12.5M with participation from Cycad Group, Nextech Invest, Mérieux Développement, Momentum Biosciences, and Novartis Venture Fund
Series B (2014): $21M led by Novartis Venture Fund, Cycad Group, Nextech Invest, and Mérieux Développement
Private Equity (2016): $5.3M, investors not publicly disclosed
Private Equity (2017): $7.7M, investors not publicly disclosed
Debt (2020): $150K backed by PPP
Other Financing Round (2021): $12.8M with participation from Theravance Respiratory Company, Adage Capital Management, Cycad Group, Jim Pallotta, and Norgine
Key Investors in ImaginAb
Cycad Group
Cycad Group is a venture capital firm focused on investing in technology across various sectors, including healthcare and energy, with a strategy centered on leveraging cutting-edge solutions to address unmet market needs.
Nextech Invest
Nextech Invest is a Zurich-based firm dedicated to accelerating advancements in precision medicine by identifying and nurturing transformative cancer medicine companies during critical stages of scientific validation.
Novartis Venture Fund
The venture arm of the global pharmaceutical manufacturer Novartis, this fund specializes in supporting innovative healthcare solutions and research-driven treatments to improve patient outcomes worldwide.
What's next for ImaginAb?
Looking ahead, the infusion of capital from the latest round positions ImaginAb to scale its operational capabilities and expand its clinical trial footprint. The company is expected to prioritize the validation of its lead candidates, moving toward broader commercial adoption within the global oncology market. Given the current enterprise-level funding context, the firm is likely to focus on strategic partnerships with major pharmaceutical entities to integrate its imaging solutions into standard-of-care protocols. By maintaining its focus on scientific rigor and clinical utility, ImaginAb is well-positioned to capitalize on the growing demand for precision diagnostics, ultimately driving long-term value for stakeholders and patients alike.
See full ImaginAb company page
